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Abstract 
Parkinson’s disease (PD) is a progressive neurodegenerative disease. Levodopa in combination with 
amantadine has a demonstrated efficacy in motility impairment. An extensive investigation of some 
enzymes described to be upregulated or downregulated in PD was made – adenylate kinase (AK), adenine 
phosphoribosyltransferase (APRT), ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), 
nucleoside-diphosphate kinase 3 (NDK3), purine nucleoside phosphorylase 1 (PNP1), and ecto-5’-
nucleotidase (NT5E). Also, creatine kinase (CK) was included in the study because it is one of the main 
enzymes involved in the regulation of the nucleotide ratio in energy metabolism. To date, there is no 
proven link between amantadine treatment of PD and these enzymes. Because there are many AKs 
isoforms modified in PD, the AK was the first investigated. The molecular docking experiments allow the 
analysis of the selective binding of amantadine – unionized (with –NH2 group) and ionized form (with –
NH3
+
 group) – to the AKs’ isoforms implicated in PD. Using available X-ray 3D structures of human AKs in 
closed-conformation, it was demonstrated that there are notable differences between the interactions of 
the two forms of amantadine for the zebrafish AK1 (5XZ2), human AK2 (2C9Y), human AK5 (2BWJ), and AK 
from B.stearothermophilus. The cytosolic human AK1 and human AK2 mostly interact with ionized 
amantadine by AMP binding residues. The human AK5 interaction with ionized amantadine does not 
involve the residues from the catalytic site. Among other enzymes tested in the present study, APRT 
revealed the best results in respect of binding amantadine ionized form. The results offer a new 
perspective for further investigation of the connections between amantadine treatment of PD and some 
enzymes involved in purine metabolism. 
©2020 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Introduction 
Parkinson’s disease (PD) is an idiopathic neurodegenerative and progressive disease, which mainly 
produces motility impairment with bradykinesia, tremor, and postural instability [1,2]. In PD, the 
neurotransmitter dopamine is reduced as a result of the degeneration of the dopaminergic neurons from 
the substantia nigra [3]. The PD-related drug utilization and PD-related other degenerative diseases are 
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due to the losses/impairment of the dopamine action at the basal ganglions [4,5]. Also, some toxins (6-
hydroxydopamine) are identified to induce dopaminergic cell death [6–8]. PD is a chronic disease with no 
curative treatment of the underline disease. Therefore is an ongoing interest in founding the most efficient 
strategy for treatment the motility disorders and other symptoms [9–14]. The drugs used in the treatment 
of PD should correct the dopamine/cholinergic balance, because the level of dopamine in the caudate-
putamen in the striatum is considerably reduced, with the exacerbation of the cholinergic control [15,16]. 
The most used dopaminergic drugs are levodopa, bromocriptine, and amantadine whereas the main anti-
cholinergic drug is trihexyphenidyl [17–20]. 
 Levodopa, discovered in 1950, was first approved in PD treatment by the FDA (U.S. Food and Drug 
Administration) in 1975 in combination with carbidopa, on the product called Sinemet [21]. An important 
side effect of long-term use of levodopa is levodopa-induced dyskinesia [22]. In this case, amantadine is 
the only treatment option that has been shown to be effective [23]. According to DrugBank 
(https://www.drugbank.ca/), amantadine (accession number DB00915) is not only an antiviral used for 
prophylaxis and treatment in infections with influenza A but, also an effective antiparkinsonian in 
combination with levodopa. The mechanism of action of amantadine is not entirely understood. According 
to PubChem (https://pubchem.ncbi.nlm.nih.gov/), amantadine (PubChem CID 2130) stimulates the release 
of dopamine from striatal dopaminergic nerve terminals and inhibits the pre-synaptic uptake of dopamine.  
In neurodegenerative diseases, among other biomarkers, some AKs isoforms are dysregulated. There is 
demonstrated that in stages 3-6 of the PD there is a down-regulation of the AK2, AK3 and AK4 in the 
substantia nigra. Also, there is a reduced expression of adenine phosphoribosyltransferase (APRT), 
ectonucleoside triphosphate diphosphorylase 1 (ENTPD1), nucleoside-diphosphate kinase 3 (NDK3) and 
purine nucleosise phosphorylase 1 (PNP1) mRNA. On contrary, the stages 5-6 of PD are characterized by 
the up-regulation of the AK1, AK5, nucleoside-diphosphate kinase 5 (NDK5), ecto-5’-nucleotidase (NT5E) 
and purine nucleoside phosphorylase 1(PNP1) [24]. As the changes in the purine metabolism influence the 
evolution of PD and, ultimately, the effectiveness of the treatment, the study of human AKs isoforms and 
enzymes involved in the purine metabolism is of great interest.  
The present study aimed to analyze the connection between the dysregulated enzymes in different 
stages of PD and amantadine. It is noteworthy that different AKs isoforms are modified in PD. The 
elements that link the AK1 and AK2 isoforms and amantadine are dyskinesia and inflammation. AK1 and 
AK2 isoforms are altered in other muscle diseases – Duchenne muscular dystrophy – or in intense physical 
activity [25–30]. It has long been known, on the one hand, the positive role or amantadine in managing 
dyskinesia from PD and, on the other hand, the AK1 and AK2 dysregulation in PD. However, to date, there 
is no proven link between amantadine and AK in PD. Before planning a strategy that implies costly and 
time-consuming experiments, the molecular docking experiments were chosen to perform the present 
study.  
The AK was the first enzyme analyzed because the specific conformational movements of the AKs 
during catalysis are well studied and there are many X-ray 3D structures of these conformations of the AKs 
deposed in the Protein Data Bank (PDB). Therefore, molecular docking, despite the limitations of the 
method, allows a first look at the connection between PD, amantadine, and some enzymes already 
demonstrated to be dysregulated in PD. We analyzed the amantadine ionized form (with –NH3
+ group) 
because the amantadine is ionized in physiological conditions [31]. 
To verify the hypothesis of that amantadine specifically target some enzymes modified in PD, the 
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following enzymes were analyzed – adenylate kinase (AK), adenine phosphoribosyltransferase (APRT), 
ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), nucleoside-diphosphate kinase 3 (NDK3), 
purine nucleoside phosphorylase 1 (PNP1), and ecto-5’-nucleotidase (NT5E). More, because in skeletal 
muscle AK1 and creatinine kinase (CK) are the main enzymes involved in the regulation of nucleotide ratio 
in energy metabolism, the molecular docking of CK was an additional analysis [27]. 
Experimental  
The study workflow is as follows: (1) retrieving and analysis of the enzymes with X-ray 3D crystalline 
structure deposed in public databases, (2) molecular docking procedure with amantadine ionized form 
(with –NH3
+
 group), (3) redocking of the substrates/substrates analogs with AKs, (4) multiple sequences 
alignment of AKs, (5) retrieving and analysis of the APRT, ENTPD1, NDK3, PNP1, NT5E, and CK with X-ray 3D 
crystalline structure deposed in public databases, (6) molecular docking procedure with amantadine 
ionized form (with –NH3
+ group) of the following enzymes: APRT, ENTPD1, NDK3, PNP1, NT5E, and CK. 
Adenylate kinase (AK) 
The human AKs isoforms and selected other AKs from other organisms were retrieved from the PDB 
(https://www.rcsb.org/). The characteristics of the AKs tested (PDB ID(s) 2C95, 1Z83, 5XZ2, 2C9Y, 2AR7, 
2BBW, 2BWJ, 3HPQ, and 1ZIP) are synthesized in Table S1 [32–34]. 
Human adenine phosphoribosyltransferase (APRT)  
The human APTRs co-crystallized with the substrate AMP and with adenine, allow a deep view of the 
amantadine interactions with the residues involved in catalysis The X-ray crystal structures of the APTRs 
included in the study (PDB ID(s) 1ORE, 1ZN7, 1ZN8, 1ZN9, 4X44, and 6FCI) are presented in the Table S2 
[35–37].  
Human ecto-5’-nucleotidase (NT5E)  
The human NT5Es co-crystallized with the substrate adenosine and with phosphomethylphosphonic 
acid adenosyl ester, allow a deep view of the amantadine interactions with the residues involved in 
catalysis. The X-ray crystal structures of the NT5Es included in the study (PDB ID(s) 4H2I, 4H2G, 4H2F, and 
4H1S) are presented in the Table S3 [38,39].  
Human ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1)  
The human NDK3s in closed-conformation and without ligands allows a thorough analysis of the 
amantadine interactions with the catalytic site. The X-ray crystal structures of the NDK3s included in the 
study (PDB ID(s) 1ZS6, 2HVD, 2HVE, 1JXV, and 3BBB) are presented in the Table S4 [40–42]. 
Human purine nucleoside phosphorylase 1 (PNP1)  
The many X-ray 3D structures of human PNP1 co-crystallized with the substrate or analag substrate 
allows a good interpretation of the molecular docking results of amantadine with PNP1. The X-ray crystal 
structures of the PNP1s included in the study (PDB ID(s) 1ULA, 1ULB, 2A0W, 2A0X, 2A0Y, 1RSZ, and 1RFG) 
are presented in the Table S5 [43–45].  
Creatinin kinases (CK)  
Due to the different isoforms of the CKs, all these isoforms were selected. X-ray 3D structures of human 
CKs are compared to CKs of other organisms, due to the small number of human CKs structures deposed in 
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PDB. The X-ray crystal structures of the CKs included in the study (PDB ID(s) 1CRK, 4Z9M, 2CRK, 1I0E, 1U6R, 
3DRB, 3DRE, 1QH4, and 1G0W) are presented in the Table S6 [46–52].  
Inclusion and exclusion criteria 
Inclusion criteria: The human AKs and AKs form other eucaryotes with X-ray 3D structure in closed-
conformation – co-crystallized with substrate or analog substrate. For further comparison, AK1 from 
zebrafish (Danio rerio) and two bacterial AKs in closed-conformation were included – one from a Gram-
negative bacteria, E.coli, and one from a Gram-positive bacteria, B.stearothermophilus. Other human 
enzymes described to be dysregulated in PD (APRT, NT5E, ENTPD1, NDK3, and PNP1). The human CKs were 
also tested because their major role in nucleotide ratios in muscles. When enzyme of human origin was not 
found in PDB, the same enzyme of other origin was retrieved.  
Exclusion criteria: Human AKs in open conformation or with no X-ray 3D structure records in public 
databases. AKs from other organisms with the exception of the AKs selected in the inclusion criteria for 
further comparisons.   
Molecular docking procedure 
Adenylate kinases preparation as receptors 
For the present study were selected from PDB Database (https://www.rcsb.org/) the AKs 3D structures 
in closed conformation – co-crystallized with substrate or analog substrate. The AKs X-ray 3D structures 
downloaded from the PDB Database as pdb files were prepared as receptors. All solvent molecules, the 
ions and the substrates were removed. In the case of multimeric AKs, only the chain that was crystallized 
with substrate or substrate analog was selected. Three chains were selected for human AK5 2BWJ – chains 
B, C, and F – all three crystallized with AMP but with different interactions with AMP. Thus, in 3D crystal 
structure from PDB, two residues in the chain B form hydrophobic interaction with AMP (Gln29 and His39) 
and the Gln29 in the chain F forms a hydrophobic interaction with AMP and no interaction with AMP for 
chain C.  
Ligand preparation 
The 3D structure of ligands was retrieved from the PubChem Compound Database 
(https://www.ncbi.nlm.nih.gov/pccompound/). Molecular docking experiments were performed with the 
unionized amantadine (PubChem CID 2130) and ionized amantadine (with –NH3
+) as ligand. The ionized 
amantadine was prepared in BIOVIA program by adding one hydrogen ion to the unionized amandatine 
structure. The redocking experiments were performed with the substrate/substrate analog with which the 
AKs were co-crystallized in the PDB; the 3D structure of the ligands was downloaded from the PDB 
Database as sdf file and visualize it on Dassault Systèmes BIOVA program – Discovery Studio Modeling 
Environment, Release 2017, San Diego: Dassault Systèmes, 2016 (http://accelrys.com). Further 
preparations for molecular docking were done by AutoDockTools.  
Molecular docking protocol 
Protein-ligand docking experiments were performed with the AutoDock4.2 program, distributed as 
open source under a GPL license (http://autodock.scripps.edu)[53–55]. The molecular docking data 
analysis was made on Windows platform using the Dassault Systèmes BIOVA program. Also, Cygwin DLL 
(cygwin1.dll) terminal was used for the running of molecular docking scripts on Windows platform. The 
molecular docking algorithm employed was with a rigid AKs structure and a ligand flexibility with 1-6 
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number of torsion and aromaticity criterion at 7.5’. The searching parameter was the Lamarckian Genetic 
Algorithm (LGA), with a maximum of 2,500,000 energy evaluations. Other docking parameters were used 
as defaults.   
Multiple sequence alignment 
Multiple sequence alignment was performed by Clustal Omega program (https://www.ebi.ac.uk/-
Tools/msa/clustalo). 
Results and Discussion 
The molecular docking of AKs with amantadine ionized form (with –NH3
+
 group) and the redocking 
experiments with substrates or analog substrates 
There are nine human AKs isoforms described until now, but only those isoforms with X-ray 3D 
structure solved were further analyzed by molecular docking. The results of human AKs were compared 
with AKs from other organisms. The AKs with 3D structure co-crystallized with substrates or analog 
substrates are optimal for our study because the AK is in closed-conformation, with the flexible LID domain 
covering the substrate. Because the study was designed based on the AKs in closed-conformation, the 
redocking experiments of AKs with its substrate or analog substrate were performed. The energy binding 
(ΔG) and the inhibition constant (Ki) of the best conformation of the complex AK-amantadine and the 
complex AK-ligand after redocking allowed a first view of the interaction of amantadine with AKs (Table 1).  
Table 1. The energy binding (ΔG) and inhibition constant (Ki) of the best conformation of the complex AK - 






















Human cytosolic AKs 
AK1 2C95 -6.19 29.04 μM -6.47 18.1 μM -10.95 9.36 nM 
AK2 1Z83 -5.97 42.33 μM -6.05 36.94 μM -11.14 6.87 nM 
AK5 2BWJ -6.79 12.61 μM -7.03 7.03 μM -4.46 534.4 μM 
Human mitochondrial AKs 
AK2 2C2Y -6.00 39.68 μM -6.25 26.29 μM -7.38 3.91 μM 
AK4 2BBW Not performed Fail 
Zebrafish AK 
AK1 5XZ2 -5.51 91.53 μM -5.69 67.9 μM -13.2 209.44 pM 
Bacterial AKs 
E.coli 3HOQ -6.55 15.78 μM -6.38 21.21 μM -5.62 75.52 μM 
B.stearothermophilus 1ZIP -5.87 49.41 μM -5.77 59.42 μM -7.2 5.3 μM 
1
Redocking with the substrates co-crystallized in PDB X-ray 3D structures. 
Redoking of the AKs isoforms with the substrates co-crystallized in the X-ray 3D structures 
The redocking process allows verifying the docking parameters. Because the AK undergoes 
conformational changes during catalysis, the substrate does not perfectly fit with the PDB conformation on 
redocking experiments. One explanation is that the crystal structure was solved by an analog substrate, not 
by the AMP and ATP. The flexibility of the AK is very well studied. During the phosphoryl transfer, the two 
small peripheral domains of the AK (NMB binding domain and LID domain) move to close the ATP binding 
region. The AMP is tightly bound to the AMP site when the AMP domain undergoes minor movements. 
Contrary, when the ATP loosely bounds to the ATP site, the large movements of the LID domain occurs – 
~30 °C and 88° hinge bending rotation – then the LID domain closed tightly upon ATP [56]. However, 
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observing the redocked conformations permits the chosen of the most suitable 3D structure when two 
closed-conformation of the same enzyme, co-crystallized with different substrates or analog substrates, 
was found in PDB. This is the case of AK isoform 1 for which there are three closed-conformation 
structures – two for human enzyme and one for zebrafish counterpart. The best redocked conformations 
are for the AKs co-crystallized with bis(adenosine)-5’-pentaphosphate (Ap5A) – 1X83 and 5XZ2 (Figure 1). 
The availability of three different conformation of the AK1 – an AK isoform dysregulated in PD – provides a 
substantial advantage for further analyses. 
   
(a) 5XZ2 (zebrafish AK1) (b) 1X83 (human AK1) (c) 2C95 (human AK1) 
Figure 1. The comparative interactions of the AK1 isoforms with the analog substrates (Ap5A or B4P) after 
redocking. The redocked conformations are shown in yellow. (a) zebrafish AK1 (PDB ID 5XZ2); (b) human AK1 
(PDB ID 1X83); (c) human AK1 (PDB ID 2C95). 
The human AK2 isoform (PDB ID 2C9Y) is found in closed-conformation only co-crystallized with P1, P4-
Di(adenosine)tetraphosphate (B4P). The redocking of the B4P substrate as ligand demonstrate that the 
parameters specified in the docking method are reasonable even there is not a perfect match with the X-
ray 3D structure from the PDB (Figure 2a). The human AK5 isoform (PDB ID 2BWJ) is deposed in PDB only 
co-crystallized with one substrate – AMP. Therefore, the enzyme is in semi closed-conformation. The 
redocking of the AMP does not show the same interactions as the X-ray 3D structure deposed in PDB 
(Figure 2b). The explanation could reside in the semi closed-conformation of the 2BWJ – the 3D structure 
contains only one substrate AMP, the substrate that causes minor movements of the AMP domain [56]. 
The semi-closed conformation of the human AK5 is one limitation of the present study, which relies on the 
X-ray 3D structure on closed-conformation.  
  
(a) 2C9Y (human AK2) (b) 2BWJ (human AK5) 
Figure 2. (a) The interactions comparative of the human AK2 (PDB ID 2C9Y) with the B4P after redocking; (b) 
The comparative interactions of the human AK5 (PDB ID 2BWJ) with the AMP after redocking. The redocked 
conformations are shown in yellow. 
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The redocking of the analog substrate Ap5A as a ligand with AKs from E.coli and B.stearothermophilus 
does not perfectly match with the conformation of the Ap5A from the X-ray 3D structure deposed in PDB 
(Figure 3). Despite this limitation, the closed-conformation of AK is the best choice when performing 
molecular studies involving this enzyme. Furthermore, the present study’s results allow the comparison of 
the interaction of the human AKs and bacterial AKs with amantadine.  
The AK4 is also named AK3-like and is a GTP:ATP phosphotransferase (EC 2.7.4.10) [57–59]. The 
mitochondrial human AK4 (PDB ID 2BBW) was deposed on PDB in closed-conformation co-crystallized with 
diguanosine-pentaphosphate (GP5). The AK4 has some characteristics that differentiate it from other AK 
isoforms, the most significant being its catalytic activity (a ribonucleoside 5'-diphosphate + ATP = a 
ribonucleoside 5'-triphosphate + ADP) (https://www.uniprot.org/uniprot/P27144). Because the 
parameters in the input file do not allow substrate redocking, the molecular docking of amantadine with 
AK4 was not made.   
 
  
(a) 3HPQ (E.coli AK) (b) 1ZIP (B.strearothermophilus AK) 
Figure 3. The comparative interactions of the bacterial AKs with the analog substrate Ap5A after redocking. 
The redocked conformations are shown in yellow. (a) E.coli AK (PDB ID 3HPQ); (b) B.stearothermophilus AK 
(PDB ID 1ZIP). 
Molecular docking of ionized amantadine with AK1 
The three X-ray 3D structures of the AK1 were analyzed for their interaction with ionized amantadine 
(with –NH3
+ group). The human AK1 co-crystallized with Ap5A (PDB ID 1Z83) mostly interacts with ionized 
amantadine with the residues involved in AMP binding. Thus, the enzyme forms van der Waals forces with 
Thr39, Tyr95, and Pro96; conventional hydrogen bonds with Gly94 and Gln101; and an unfavorable 
positive-positive interaction with Arg97. In total, there are five residues from the NMP binding region that 
interact with ionized amantadine – Thr39, Gly40, Leu43, Leu66, and Val67 (Figure 4). A comparison of the 
AK1 (PDB ID 1Z83) interactions with the two forms of amantadine, reveals that the group –NH3
+ of the 
ionized amantadine is involved in three conventional hydrogen bonds like the –NH2 group of the unionized 
form. The difference lies in the residues involved in these interactions – Val67 interacts with –NH2 of 
unionized amantadine, respectively Gln94 and Gln101 with –NH3
+ of ionized amantadine.  




Gln101:OE1-H27 2.26 Å 
Gln101:OE1-H5 2.09 Å 
Gly94:O-H27 1.92 Å 
Leu43 4.93 Å 
Leu66 4.48 Å 
Val67 4.68 Å 
Val72 5.05 Å 
Arg97 5.46 Å 
Leu43-C9 4.34 Å 
Val67-C9 3.78 Å 
Val72-C9 3.74 Å 
Arg97:NH2-N1 5.46Å 
 
(a) (b) (c) 
Figure 4. Interactions of ionized amantadine with human AK1, PDB ID 1Z83. (a) 3D display of ionized 
amantadine interaction as ligand with the 1Z83 residues; (b) code color for interactions: in green are shown 
conventional hydrogen bonds, light green – van der Waals forces, mauve – alkyl hydrophobic interactions, red 
– unfavorable positive-positive interactions; (c) the distances (Å) of the 1Z83 - ionized amantadine 
interactions. 
The human AK1 co-crystallized with B4P (PDB ID 2C95) forms an electrostatic interaction between 
Glu62, a residue belonging to NMP binding region, and –NH3
+
 group of ionized amantadine. The same 
residue, Glu62, interacts with the –NH2 group of the unionized amantadine by two conventional hydrogen 
bonds. In contrast with human AK1 (PDB ID 1Z83), the human AK1 (PDB ID 2C95) interacts with ionized 
amantadine with residues belonging to NMP binding region (Arg44, Val47, Ser58, Met61, and Glu62) and 
LID domain (Gly137, Arg138, Val139, and Asp140). More, AK1 (PDB ID 2C95) interacts with only two AMP 
binding residues – Arg44 and Arg138 (Figure 5).  
 
 
Glu62:OE2-H27 1.75 Å 
Arg44 4.10 Å 
Arg44 4.63 Å 
Val47 5.33 Å 
Met61 4.12 Å 
Arg138-C9 4.45 Å 
Val139-C9 4.55 Å 
 
(a) (b) (c) 
Figure 5. Interactions of ionized amantadine with human AK1, PDB ID 2C95. (a) 3D display of ionized 
amantadine interaction as ligand with the 2C95 residues; (b) code color for interactions: in orange are shown 
the salt bridge, light green – van der Waals forces, mauve – alkyl hydrophobic interactions; (c) the distances 
(Å) of the 2C95 - ionized amantadine interactions. 
The zebrafish AK1 co-crystallized with Ap5A (PDB ID 5XZ2) shows much more differences regarding the 
interactions with ionized amantadine, no residue which interacts with unionized amantadine interact with 
ionized amantadine. In contrast with unionized amantadine, the –NH3
+ group of the ionized amantadine 
interacts with the residues involved in catalysis – one residue from the NMP binding region, Met61, forms 
a conventional hydrogen bond and Asp140 from the LID domain forms two electrostatic interactions. 
Similar to human AK1 (PDB ID 2C95), the zebrafish AK1 interacts with ionized amantadine by residues from 
the NMP binding region (Leu43, Met61, Gly64, Glu65, Leu66, and Val67) and with residues from the LID 
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region (Arg138 and Asp140). Most of the residues that interact with ionized amantadine are AMP binding 
residues – Gly64, Glu65, Leu66, Val67, Arg 138, and Arg 149 (Figure 6). 
 
  
Met61:O-H5 2.01 Å 
Asp140:OD2-H27 2.10 Å 
Asp140:OD2-H28 2.07 Å 
Met61 4.02 Å 
Leu66-C9 5.10 Å 
 
(a) (b) (c) 
Figure 6. Interactions of ionized amantadine with zebrafish AK1, PDB ID 5XZ2. (a) 3D display of ionized 
amantadine interaction as ligand with the 5XZ2 residues; (b) code color for interactions: in green are shown 
conventional hydrogen bonds, orange – salt bridge, light green – van der Waals forces, mauve – alkyl 
hydrophobic interactions; (c) the distances (Å) of the 5XZ2 - ionized amantadine interactions. 
Molecular docking of ionized amantadine with human AK2 
Human AK2 (PDB ID 2C9Y) shows different interactions with the two forms of amantadine. The –NH3
+
 
group forms a conventional hydrogen bond with a residue from the AMP binding region (Val74) and two 
electrostatic interactions with Asp76. Two residues from the AMP binding region form alkyl interactions 
(Arg103 and Phe101). Unlike unionized amantadine, the ionized amantadine shows a better match with 
the residues from the catalytic site. Ionized amantadine interacts with five AMP binding residues – Thr44, 
Val74, Phe101, Arg103, and Gln107 (Figure 7). 
 
 
Val74:O-H5 1.96 Å 
Asp76:OD1-H27 2.17 Å 
Asp76:OD1-H28 2.15 Å 
Val79 5.40 Å 
Val79 4.46 Å 
Val79-C9 3.69 Å 
Arg103 4.76 Å 
Phe101 4.64 Å 
 
(a) (b) (c) 
Figure 7. Interactions of ionized amantadine with human AK2, PDB ID 2C9Y. (a) 3D display of ionized 
amantadine interaction as ligand with the 2C9Y residues; (b) code color for interactions: in green are shown 
conventional hydrogen bonds, orange – salt bridge, light green – van der Waals forces, mauve – alkyl 
hydrophobic interactions; (c) the distances (Å) of the 2C9Y-ionized amantadine interactions. 
Molecular docking of ionized amantadine with human AK5 
Unlike unionized amantadine, the ionized amantadine interacts with human AK5 (PDB ID 2BWJ-chain B) 
residues that do not belong to the domains involved in catalysis. The van der Waals forces are observed 
with two glycines in the phosphate-binding loop (P-loop) (Figure 8). 




Asp122:OD1-H27 1.98 Å 
Asp122:OD1-H5 2.17 Å 
Met128 5.35 Å 
Cys120-C10 5.26 Å 
Ile164-C10 5.40 Å 
Tyr156 4.65 Å 
Tyr156 4.66 Å 
Tyr156-C10 4.40 Å 
Tyr157 5.08 Å 
Cys123:HN-H5 2.35 Å 
 
(a) (b) (c) 
Figure 8. Interactions of amantadine with human AK5, PDB ID 2BWJ. (a) 3D display of ionized amantadine interaction 
as ligand with the 2BWJ residues; (b) code color for interactions: in orange are shown salt bridge, light green – van der 
Waals forces, mauve – alkyl hydrophobic interactions, red – unfavorable donor-donor interactions; (c) the distances 
(Å) of the 2BWJ - ionized amantadine interactions. 
Molecular docking of ionized amantadine with bacterial AKs  
A comparison of human AKs with their bacterial counterparts was necessary to draw a valid conclusion 
about the specificity of human AKs for amantadine. Bacterial AKs with X-ray 3D structure deposited in PDB 
are much numerous than AKs from eucaryotes. AK from E.coli (PDB ID 3HPQ) interacts with ionized 
amantadine through residues that do not belong to the catalytic site. Only Ala8 (from the P-loop) forms 
two alkyl hydrophobic interactions with ionized amantadine (Figure 9). 
 
  
Phe109:O-H5 3.07 Å 
Glu108:OE2-H27 2.16 Å 
Glu108:OE2-H25 2.13 Å 
Asp110:OD1-H28 1.89 Å 
Ala8 4.31 Å 
Ala8-C9 3.27 Å 
Tyr171-C9 4.30 Å 
His172 5.36 Å 
His172-C9 5.39 Å 
 
(a) (b) (c) 
Figure 9. Interactions of ionized amantadine with AK from E.coli, PDB ID 3HPQ. (a) 3D display of amantadine 
interaction as ligand with the 3HPQ residues; (b) code color for interactions: in green are shown conventional 
hydrogen bonds, orange – salt bridge, light green – van der Waals forces, mauve – alkyl hydrophobic 
interactions; (c) the distances (Å) of the 3HPQ - ionized amantadine interactions. 
AK from B. stearothermophilus (PDB ID ZIP) interacts with ionized amantadine from two residues 
belonging to the LID region – with Arg162 by two electrostatic interactions and with Arg160 by van der 
Waals forces. The Pro9 from the P-loop forms alkyl interactions with ionized amantadine. Also, four 
residues from the NMP binding region interact with ionized amantadine – Met53, Leu58, Gly56, and 
Arg171. More, five AMP-binding residues interact with ionized amantadine – Gly56, Asp57, Leu58, Arg88, 
and Arg171 (Figure 10).  
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Met53:O-H5 2.07 Å 
Asp162:OD2-H27 2.12 Å 
Asp162:OD2-H28 2.15 Å 
Arg171 5.23 Å 
Leu58 4.94 Å 
Pro9-C10 4.78 Å 
Arg171-C10 4.41 Å 
 
(a) (b) (c) 
Figure 10. Interactions of ionized amantadine with AK from B.stearothermophilus, PDB ID 1ZIP. (a) 3D display 
of amantadine interaction as ligand with the 1ZIP residues; (b) code color for interactions: in green are shown 
conventional hydrogen bonds, orange – salt bridge, light green – van der Waals forces, mauve – alkyl 
hydrophobic interactions; (c) the distances (Å) of the 1ZIP - ionized amantadine interactions. 
Comparison of molecular docking of ionized amantadine with the AKs studied 
The overall comparison of the molecular docking results offers a better view of the interactions of the 
two forms of amantadine with the human and bacterial AKs. As the physiological form of amantadine is 
ionized, the comparison of molecular docking results with both forms of the drug has advanced the study 
on the hypothesis of the AK – amantadine – PD connection. Among the AKs included in the present study 
the zebrafish AK1 (PDB ID 5XZ2), human AK2 (PDB ID 2C9Y), human AK5 (PDB ID 2BWJ), and AK from 
B.stearothermophilus (PDB ID 1ZIP) show the most differences in interactions with the two forms of 
amantadine (Figure 11). 
Multiple sequence alignment of the AKs isoforms 
The multiple sequence alignment allows an overview of the interactions of the two forms of 
amantadine with the AKs isoforms. The residues involved substrate binding are well conserved among 
bacterial AKs and eucaryotes AKs. The interaction of unionized amantadine with zebrafish AK1 and human 
AK4 mainly involves the residues from the LID region that interact with unionized amantadine. In contrast, 
the human AK1, and AK5 interact with unionized amantadine through AMP binding residues. Minor 
similarities are noticed between human AK2 and AK from E.coli, both of which have two residues in the 
phosphate-binding loop (P-loop) that interact with unionized amantadine – one residue glycine being 
identical for the two enzymes. Also, human AK1 shows some similarities with human AK4 with three 
different residues from the LID region.  
An in-depth analysis of the two forms of ionized amantadine shows that, except for AK5 (PDB ID 2BWJ), 
the ionized amantadine interacts predominantly with AMP binding residues. Among AK1 isoforms, the 
interactions with ionized amantadine are not similar. The AK2 (PDB ID 2C9Y) and the B.stearothermophilus 
AK (PDB ID 1ZIP) show a better match with the residues at the catalytic site with the ionized amantadine. 
Unlike unionized amantadine, the ionized amantadine interacts with more AMP binding residues of AK1 
and AK2 isoforms (Figure 12).  
 
 

















Figure 11. Interactions of unionized and ionized amantadine with AKs. (a) human AK1 (PDB ID 2C95); (b) 
human AK1 (PDB ID 1Z85) (c) zebrafish AK1 (PDB ID 5XZ2); (d) human AK2 (PDB ID 2C9Y); (e) human AK5 (PDB 
ID 2BWJ) (f) AK from E.coli (PDB ID 3HPQ); (g) AK from B.stearothermophilus (PDB ID 1ZIP); unionized 
amantadine is shown in yellow.   
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Figure 12. Multiple sequence alignment of the AKs sequences. In gray background are marked the residues 
belong to Walker A motif – phosphate-binding loop or P-loop; in yellow background is marked the NMP 
binding region and the residues that belong to AMP binding region are italic-bolded; in blue background is 
marked the LID region; with red are marked the residues (van der Waals, conventional hydrogen bond or alkyl 
interactions) which interact with amantadine ionized form (with –NH3
+
 group); the residues which interact 
with amantadine unionized form (with –NH2 group) are bolded-underlined; the residues which interact with 
amantadine unionized and ionized are red and bolded-underlined; AKEC is AK from E.coli; AKBS is AK from 
B.stearothermophilus; with dot “.” are marked the semi-conservative replacements; with colon “:” are marked 
the conservative replacements; with “*” are marked the identities of the residues.  
Molecular docking of the human adenine phosphoribosyltransferase with ionized amantadine and the 
redocking with the substrates 
The human APRTs (E.C. 2.4.2.7) found in PDB were analyzed for the amantadine interactions. The 
enzyme catalyses the reaction: AMP + diphosphate = 5-phospho-alpha-D-ribose 1-diphosphate + adenine. 
In the adenine metabolism, APRT is involved in the first stage of the subpathway that synthesizes AMP 
from adenine (UniProtKB P07741). Thus, in adenine metabolism, APRT is closely connected with AK by the 
substrate AMP. Therefore, the APRT was the first enzyme tested to verify the hypothesis that amantadine 
specifically binds some human AKs isoforms. First, the redock of the substrates co-crystallized in the X-ray 
3D structures was made. Then, amantadine ionized form was tested and the interactions with the residues 
from the catalytic site (Table2). 
Among the four PDB structure co-crystallized with adenosine monophosphate (AMP) (PDB ID(s) 1ORE, 
1ZN8, 1ZN9, and 4X44), two of them show the best interaction of amantadine with the AMP-binding 
residues. The amantadine – 1ZN9 interactions involve four residues that also bind AMP (Figure 13). 
 
 
Mihaela Ileana Ionescu  ADMET & DMPK 8(2) (2020) 149-175 
162  
Table 2. The energy binding (ΔG) and inhibition constant (Ki) of the best 












1ORE -6.44 18.93  -6.91 8.68  
1ZN9 -6.52 16.77  -6.3 24.04  
4X44 -6.01 39.53  -8.1 1.15  
1ZN8 -6.15 31.21 -7.39 3.83  
6FCI -7.33 4.26  -6.21 28.14  
1ZN7 -6.9 8.73 -5.58 81.74 
1





Leu129:O-H5 3.06 Å 
Asp127:OD2-H28 1.84 Å 
Asp128:OD1-H27 2.04 Å 
Asp128:OD1-H5 2.14 Å 
Ala131 4.03 Å 
Leu129 4.08 Å 
(a) (b) (c) 
Figure 13. Interactions of ionized amantadine with APRT co-crystallized with AMP, PDB ID 1ZN9. (a) 3D display 
of the amantadine (shows in yellow) and AMP in binding pocket; (b) code color for interactions: in green are 
shown conventional hydrogen bonds, orange – salt bridge, mauve – alkyl hydrophobic interactions; (c) the 
distances (Å) of the 1ZN9 - ionized amantadine interactions. 
Similarly, amantadine – 1ZN8 interactions involve seven AMP-binding residues. Among them, four 





Asp127:OD2-N1 2.68 Å 
Asp128:OD2-H27 2.23 Å 
Asp128:OD2-H5 192 Å  
Ala131 4.26 Å 
Leu129 4.87 Å 
Leu129 5.01 Å 
Leu103 5.45 Å 
(a) (b) (c) 
14. Interactions of ionized amantadine with APRT co-crystallized with AMP, PDB ID 1ZN8. (a) 3D display of the 
amantadine (shows in yellow) and AMP in binding pocket; (b) code color for interactions: in orange are shown 
the salt bridges, light green – van der Waals forces, mauve – alkyl hydrophobic interactions; (c) the distances 
(Å) of the 1ZN8 - ionized amantadine interactions. 
ADMET & DMPK 8(2) (2020) 149-175 Amantadine binding to the enzymes regulated in Parkinson’s disease 
doi: http://dx.doi.org/10.5599/admet.854 163 
 The other two APRT structures co-crystallized with AMP show different interactions. Among the eight 




Ser161:OG-H27 2.04 Å 
Glu180:OXT-H27 2.31 Å 
Glu180:O-H28 1.85 Å 
Val24 4.29 Å 
Val25 4.22 Å 
Val24-C9 4.28 Å 
Val25-C9 4.69 Å 
Leu159-C9 4.85 Å 
(a) (b) (c) 
Figure 15. Interactions of ionized amantadine with APRT co-crystallized with AMP, PDB ID 1ORE. (a) 3D display 
of the amantadine (shows in yellow) and AMP in binding pocket; (b) code color for interactions: in orange are 
shown the salt bridges, light green – van der Waals forces, mauve – alkyl hydrophobic interactions; (c) the 
distances (Å) of the 1ORE - ionized amantadine interactions. 
The molecular docking of amantadine with 4X44 results in similar interactions with 1ORE. There are 
three AMP-binding residues that bind amantadine (Val25, Arg27, and Leu159) (Figure 16). 
  
 
Ser161:OG-H5 2.33 Å 
Glu180:OXT-H5 2.29 Å 
Glu180:O-H27 1.90 Å 
Val24 4.81 Å 
Val25 4.78 Å 
Val25-C10 3.68 Å 
Leu159 4.86 Å 
(a) (b) (c) 
Figure 16. Interactions of ionized amantadine with APRT co-crystallized with AMP, PDB ID 4X44. (a) 3D display 
of the amantadine (shows in yellow) and AMP in binding pocket; (b) code color for interactions: in orange are 
shown the salt bridges, light green – van der Waals forces, mauve – alkyl hydrophobic interactions; (c) the 
distances (Å) of the 4X44 - ionized amantadine interactions. 
 
The human APRT co-crystallized with adenine (PDB ID(s) 6FCI and 1ZN7) allows a deeper view of the 
amantadine interactions with this enzyme. The two structures have different behavior when docked with 
amantadine. Thus, among ten residues of the 6FCI that interact with amantadine, five bind adenine 
(Glu104, Arg67, Leu129, Tyr105, and Ala131) (Figure 17). 




Leu129:O-H5 2.05 Å 
Asp127-OD1 1.75 Å 
Asp128:OD2 1.81 Å 
Ala131 5.09 Å 
Ala131-C10 3.35 Å 
Ala129 4.85 Å 
Leu103 4.29 Å 
Leu129-C10 4.47 Å 
Tyr105 5.16 Å 
(a) (b) (c) 
Figure 17. Interactions of ionized amantadine with APRT co-crystallized with adenine, PDB ID 6FCI. (a) 3D 
display of the amantadine (shows in yellow) and adenine in binding pocket; (b) code color for interactions: in 
orange are shown the salt bridges, light green – van der Waals forces, mauve – alkyl hydrophobic interactions; 
(c) the distances (Å) of the 6FCI - ionized amantadine interactions. 
Contrary, in the case of 1ZN7 structure, molecular docking of amantadine involves different residues 
than adenine (Figure 18). The last two structures (PDB ID(s) 6FCI and 1ZN7), being co-crystallized with 




Asp115:O-H27 1.83 Å 
Glu118:OE1-H27 2.03 Å 
Glu118:OE1-H5 2.15 Å 
Asp115:OD2-N1 5.51 Å 
Glu118:OE1-N1 4.30 Å 
Tyr60 4.30 Å 
Tyr60-C9 5.28 Å 
(a) (b) (c) 
Figure 18. Interactions of ionized amantadine with APRT co-crystallized with adenine, PDB ID 1ZN7. (a) 3D 
display of the amantadine (shows in yellow) and adenine in binding pocket; (b) code color for interactions: in 
orange are shown the salt bridges, light green – van der Waals forces, mauve – alkyl hydrophobic interactions; 
(c) the distances (Å) of the 1ZN7 - ionized amantadine interactions. 
 
Molecular docking of the human ecto-5’-nucleotidase (NT5E) with ionized amantadine and the redocking 
with the substrates 
The ecto-5’-nucleotidase (NT5E) (E.C. 3.1.3.5) catalyzes the hydrolysis of extracellular AMP to 
adenosine. All human NT5Es found in PDB were analyzed about the amantadine interactions. First, the 
redock of the substrates co-crystallized in the X-ray 3D structures was made, then amantadine ionized form 
molecular docking (Table 3). In all NT5Es structures analyzed, the amanatdine binds other residues than the 
substrate-binding region (data not shown).  
Molecular docking of the human ectonucleoside triphosphate diphosphohydrolase 1 with ionized 
amantadine and the redocking with the substrates 
The ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) (E.C. 3.6.1.5) catalyzes the reaction: a 
ribonucleoside 5’-triphosphate + 2H2O = a ribonucleoside 5’-triphosphate +2H
+ + 2phosphate. Because 
there are no matching PDB entries for human ENTDP1, were analyzed the ENTDP1 from Rattus norvegicus. 
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Although the interpretation of the molecular docking of amantadine is not reliable, because the crystal 
structures are not with the substrates, it is worth noticing that the molecular docking of the 3ZX2 with 
amantadine results in an interaction with the active-site residue Glu174 by two salt bridge (Table 4).  
Table 3. The energy binding (ΔG) and inhibition constant (Ki) of the best 











4H2I -8.08 1.2 -4.91 250.92 
4H2F -7.93 1.55 -6.95 8.01 
4H2G -7.59 2.72 -5.97 42.08 
4H1S -7.12 6.08 -5.56 84.56 
1
 redocking with the substrates co-crystallized in PDB X-ray 3D structures. 
Table 4. The energy binding (ΔG) and inhibition constant (Ki) of the best 







Ki (μM)   
3ZX0 -6.6 14.56 
 
Not the case 3ZX2 -6.45 18.71 
3ZX3 -7.24 4.94 
Molecular docking of the human nucleoside diphosphate kinase 3 (NDK3) with ionized amantadine and the 
redocking with the substrates  
The nucleoside diphosphate kinase 3 (NDK3) (E.C. 2.7.4.6) catalysis the reaction: a 2’-
deoxyribonucleoside 5’-diphosphate + ATP = a 2’-deoxyribonucleoside 5’-triphosphate + ADP.  The human 
found in PDB were analyzed about the amantadine interactions (Table 5). First, the redock of the 
substrates co-crystallized in the X-ray 3D structures were made for three structures (PDB ID(s) 1ZS6, 2HVD, 
and 3BBB). In the case of 1ZS6 and 3BBB, no significant interactions of the amantadine with ATP-binding 
residues or with the histidine from the active site were observed. The 2HVD and 1JXV form van der Waal 
forces with histidine 118 from the active site (Pros-phosphohistidine intermediate) but no interactions with 
the ATP-binding residues.  
Table 5. The energy binding (ΔG) and inhibition constant (Ki) of the best conformation of the complex NDK3 - 











1ZS6 -7.34 4.15 -5.96 42.42 
2HVD -6.55 15.69 -5.81 54.99 
1JXV -7.13 5.97 not the case 














 redocking with the substrates co-crystallized in PDB X-ray 3D structures; 
2
 redock of 2’-deoxyadenosine-5’-
monophosphate; 
3
 redock of 2’-deoxyguanosine-5’-monophosphate.  
Molecular docking of the human purine nucleoside phosphorylase 1 (PNP1) with ionized amantadine and 
the redocking with the substrates 
The human purine nucleoside phosphorylase 1 (PNP1) (E.C. 2.4.2.1) catalyses the reaction: a purine D-
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ribonucleotide + phosphate = a purine nucleobase + alpha-D-ribose 1-phosphate. The reaction is part of 
purine nucleoside salvage (UniProtKB P00491). The human PNP1s retrieved from the PDB were analyzed 
about the amantadine interactions (Table 6). The molecular docking of the PNP1 structures shows no 
relevant interactions with amantadine.  Some of the PNP1 interact with amantadine with only one binding-
site residue – the 1ULB interacts with Asn243 and the 1RFG forms a salt bridge with Glu201. The 2A0W, 
2A0X, 2A0Y, 1RSZ form van der Waals interactions with only one binding-site residue - Gln201.  
Table 6. The energy binding (ΔG) and inhibition constant (Ki) of the best 











1ULA -7.31 4.35 not the case 
1ULB -6.74 11.47 -5.61 77.85 μM 
2A0W -6.52 16.57 -8.63 473.78 nM 
2A0X -6.5 17.29 -8.69 425.71 nM 
2A0Y -6.46 18.38 -8.89 306.03 nM 
1RSZ -6.41 19.92 -8.35 760.14 nM 
1RFG -6.4 20.45 -7.42 3.67 μM 
1
 redocking with the substrates co-crystallized in PDB X-ray 3D structures. 
Molecular docking of the creatine kinases (CKs) with ionized amantadine and redocking 
The CK (E.C. 2.7.3.2) catalyses the reversible reaction : ATP + creatine = ADP + H
+
 + N-phosphocreatine. 
The different CKs type (UniProtKB P11009, P17540, P00563, P06732, P12277, P05122, and Q9XSC6) 
retieved form the PDB were analysed about the amantadine interactions (Table 7). Molecular docking 
results show no interactions of amantadine with ATP-binding residues or nucleotide (ATP) - binding 
regions.  
Table 7. The energy binding (ΔG) and inhibition constant (Ki) of the best 







Ki  ΔG (Kcal/mol) Ki  
mitochondrial CK 
1CRK -6.65 13.26 μM not the case 
4Z9M -7.3 4.49 μM -8.64 462.56 nM 
muscle CK 
2CRK -7.65 2.45 μM not the case 
1IOE -5.81 54.93 μM not the case 
1U6R -6.37 21.24 μM -7.84 1.78 μM 
brain CK  
3DRB -6.39 20.63 μM not the case 
3DRE -6.99 7.57 μM not the case 
1QH4 -7.45 3.44 μM not the case 
retinal CK 
1G0W -7.12 6.07 μM not the case 
1
 redocking with the substrates co-crystallized in PDB X-ray 3D structures. 
Discussion 
The PD is an idiopathic, progressive disease of the central neurological system. The treatment of 
dyskinesia remains a critical issue in the PD treatment strategy, levodopa-induced dyskinesia being a real 
challenge for both patients and healthcare professionals. The combination of levodopa - amantadine is 
useful for the people who do not tolerate optimal doses of levodopa and allows better control of the 
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disease. Among other biomarkers modified in PD, there is a dysregulation of some human AK isoforms that 
are also altered in other muscle diseases. The AK1 and AK2 isoforms are also involved in modulation 
immunity and inflammation in many diseases. These observations formed the basis of the design of this 
study.  
Because AK is an important enzyme for energetic metabolism, its involvement in a variety of diseases is 
not surprising. Because the ATP is the most used “exchange currency” in nature, the crucial role of AK is 
energetic metabolism explains the interest in the study of this enzyme. Nine human AKs isoforms have 
been identified, each with important characteristics that differentiate them [60]. Five AKs isoforms have 
the X-ray structure deposited in public databases but only four isoforms are in closed-conformation (AK1, 
AK2, AK4, and AK5). Consequently, only the AKs in closed-conformation were selected for the present 
study – five human AKs, one AK1 from zebrafish, and two bacterial AKs.  
Experimental studies are very often costly and time-consuming, so conducting an experimental study 
without strong theoretical research is not a pragmatic approach. Molecular docking is a useful method for 
first analyzes of new protein-ligand interaction. This method allowed analysis of the selective binding of 
amantadine to the AKs’ isoforms implicated in PD. The ΔG and Ki data provide only a first view of the 
amantadine binding to different AKs. Thus, a deep analysis of the amantadine with the AKs residues 
illustrated that there are notable differences between all human AKs investigated. It was previously 
described a down-regulation of the mitochondrial isoforms AK2 and AK4 in the stages 3-6 and an up-
regulation of the cytosolic isoform AK1 in the stages 5-6, as compensation of altered purine metabolism 
(Figure 19) [24]. There are well-known motor deficits in PD – slowness of movement, muscle rigidity, and 
tremor at rest, the tremor that decreases when the body is actively engaged in purposeful activity [61]–
[63]. The cytosolic AK1 and the mitochondrial AK2 are dysregulated in different muscle pathology. In 
contrast with PD, in Duchenne muscular dystrophy – an X-linked recessive disease – there is a progressive 
weakness mainly of the pelvic girdle and shoulder girdle, pseudohypertrophy due to the infiltration by fat 
and connective tissue with immobilization at young ages and cardiomyopathy [64], [65]. The role of AK1 in 
inflammation has been demonstrated, but its role in maintaining neuroinflammation is not yet known 
(Figure 19) [66].  
 
Figure 19. The involvement of human AK1 and human AK2 in PD, inflammation, and muscle activity. The 
amantadine treatment efficacy in PD developed the hypothesis that amantadine – AK interactions.  
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According to the scientific literature, there is no connection between the amantadine and AKs in PD. 
However, because the mechanism of amantadine in PD is not yet known, the investigation of the possible 
mechanism of amantadine is of great interest. The present study was conducted with the premise that 
some markers up-regulated or down-regulated in PD could be the target for amantadine. Many studies 
described the association of some clinical symptoms with dysregulation of different enzymes. The 
observation that many AKs isoforms are altered in PD leads to the hypothesis that there is a connection 
between amantadine and these AKs isoforms. Also, other enzymes already described to be dysregulated in 
PD was investigated – APRT, NT5E, ENTPD1, NDK3, and PNP1 [24]. More, CK was included in the study 
because of its proven involvement in some muscle diseases [27]. 
Our experiments show that the human cytosolic AK1 interacts mainly with ionized amantadine by 
residues from the AMP binding region. Even if the two human AK1s analyzed do not form the same 
interactions with amantadine, the observation could be aware of the efficacy of the amantadine in the late 
stages of PD, because, as mentioned earlier, AK1 activity could compensate for purine metabolism 
dysfunctions. Regarding AK1 from other species, the zebrafish AK1 interactions with amantadine are more 
similar to those of the AK from B.stearothermophilus. Moreover, the interactions with ionized amantadine 
are different for the three AK1 enzymes analyzed. Regarding the mitochondrial human AK2, the 
interactions with ionized amantadine are most similar to AK1 (PDB ID 1Z83) with five residues in common – 
Thr44, Val74, Phe101, Arg103, and Gln107. Thus, the results of the present study highlight the relevance of 
AK1 and AK2 in PD and provide a valid perspective for further investigation of the role of amantadine in 
inhibiting these enzymes. The connection between cytosolic and mitochondrial human AKs was extensively 
studied by Dzeja et al. who made a very clear demonstration of the type ”bucket-brigade” process by 
which AK1 and AK2 isoforms facilitate the transfer of the enzyme substrates without changes in the 
metabolite concentration in the cellular compartments [67].  
It is not possible to establish the mechanism of action of amantadine in PD observing only the 
interaction of the drug with AKs, but the results of the present study provide a valuable perspective for 
understanding the pathogenesis of PD. So the next step was to analyze of a large group of proteins.  
Among the enzymes analyzed for their affinity for amantadine, APRT shows remarkable results. Because 
there are available many APRTs X-ray 3D structures co-crystallized with AMP and with adenine, we were 
able to compare the molecular docking results. The molecular docking of amantadine ionized form with 
APRTs demonstrated that amantadine interacts with AMP-binding residues. Although the structures of 
APRTs co-crystallized with adenine shows identical residues that bind amantadine and adenine, there are 
some differences between the APRTs structures tested. Contrary, the results obtained by molecular 
docking of amantadine with APRTs X-ray 3D structures co-crystallized with AMP strongly indicated that 
amantadine could target adenine metabolism.  
Here, a preliminary analysis of some key factors described in PD pathogenesis reveals that there are at 
least two enzymes involved in adenine metabolism that worth further investigation – AK and APRT. Then, 
before an experimental confirmation of the molecular docking results, a molecular dynamics simulation 
study aid to observe the proper binding of amantadine. 
The present study aimed to try to make sense of the anti-parkinsonian effects of the amantadine. The 
methods used in the present study do not elucidate the mechanism of amantadine, but demonstrate that 
in PD there is a link between amantadine and some enzymes described to be modified in different stages 
of the disease.   
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Conclusions 
The PD is a progressive neurodegenerative disease characterized mainly by motility impairment. There 
is no curative treatment but there are some therapeutic strategies for the treatment of dyskinesia, 
amantadine being used until now even for better control of levodopa-induced dyskinesia. Also, there is 
demonstrated that in the clinical evolution of PD, many enzymes are modified - some AK isoforms, APRT, 
NT5E, ENTPD1, NDK3, and PNP1. Using available X-ray 3D structures of these enzymes or their 
counterparts from other organisms, two enzymes show relevant results – AK and APRT. The closed-
conformation of the AK is most reliable due to the catalytic particularities of the enzyme – the movement 
of the domains is coordinated by the sequential addition of the substrates. The molecular docking 
experiments demonstrated that human AK1 and AK2 with ionized amantadine by AMP binding residues but 
there are notable differences between the two AK isoforms. Other AKs included in the study, further 
demonstrated the specific interaction of amantadine with human AKs. The study of amantadine interaction 
with different AKs’ isoforms has more to give. The studies of the PD highlighted that there is a relationship 
between the key factors involved in PD. Among them, mitochondrial factors have a crucial role in the 
disease pathogenesis. The APRT structures co-crystallized with AMP results in the best interactions with 
amantadine, the AMP-binding residues form strong interactions with amantadine. The results of the 
present study offer a new perspective for further investigation of the connections between amantadine 
treatment of PD and some enzymes involved in purine metabolism.  
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with substrate or 
analog substrate 
mutations reference 
AK1 2C95 Homo sapiens 194 B4P
1
; malonate ion no unpublished 







AK1 5XZ2 Danio rerio 196 Ap5A; SO4
2-
 no [32] 
AK2 2C9Y Homo sapiens 242 B4P; 1,2-ethandiol no unpublished 
AK4 2AR7 Homo sapiens 246 no no unpublished 
AK4 2BBW Homo sapiens 246 GP5 
3 
no unpublished 
AK5 2BWJ Homo sapiens 199 AMP R135M unpublished 
 3HPQ E.coli 214 Ap5A no [33] 




 no [34] 
1





Table S2. The characteristics of the APRTs included in the study. 
PDB ID Organism Residues 
co-crystallized 
with substrate or 
analog substrate 
mutations reference 



















1ZN8 Homo sapiens 180 AMP; Cl
-
  no [36] 
1ZN9 Homo sapiens 180 AMP no [36] 
4X44 Homo sapiens 180 AMP, SO4-; GOL
5 
R89Q unpublished 
6FCI Homo sapiens 180 PRP; ADE; Mg2
+
 no [37] 
1









Table S3. The characteristics of the NT5Es included in the study. 
PDB ID Organism Residues 
co-crystallized with 
substrate or analog 
substrate 
mutations reference 

















  seven [38] 








 seven [38] 






 no [39] 
1 
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Table S4. The characteristics of the NDK3s included in the study. 
PDB ID Organism Residues 
co-crystallized with 
substrate or analog 
substrate 
mutations reference 
1ZS6 Homo sapiens 169 ADP
1 
no unpublished 
2HVD Homo sapiens 152 ADP no [40] 
2HVE Homo sapiens 152 ADP S120G [40] 
1JXV Homo sapiens 152 no no [41] 












Table S5. The characteristics of the PNP1s included in the study. 
PDB ID Organism Residues 
co-crystallized with 
substrate or analog 
substrate 
mutations reference 
1ULA Homo sapiens 289 SO4
- 
no [43] 
1ULB Homo sapiens 289 guanine; SO4
-
  no [43] 




 H257G [44] 




 H257F [44] 









 no unpublished 
1RFG Homo sapiens 288 guanosine; SO4
-




Table S6. The characteristics of the CKs included in the study. 
PDB ID Residues Organism 
co-crystallized with 




1CRK  380 Gallus gallus SO4
-
 no [46] 









 no [48] 








; Mg2+ R134K [49] 
brain CK 
3DRB 381 Homo sapiens ADP; Mg2+ no [50] 
3DRE 381 Homo sapiens no no [50] 




1G0W 380 Bos taurus SO4
-




 (diaminomethyl-methyl-amino)-acetic acid 
 
